Name: 글로벌 시장 동향
SKU: MI7378
Availability: InStock

보고서 요약(국문)

개요
전 세계 분자 유방 영상 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
분자 유방 영상(scintimammography, nuclear medicine breast imaging, breast-specific gamma imaging이라고도 함)은 유방 조직이 치밀한 여성의 유방암을 진단하는 데 사용되는 FDA 승인을 받은 첨단 영상 기술입니다. 분자 유방 영상은 특수 카메라와 소량의 방사성 추적자를 사용하여 조직 활동의 차이를 포착하고 건강한 치밀 조직과 유방 이상을 구분합니다. 암세포를 놓칠 가능성이 낮은 매우 정확한 영상 검사입니다.
또한, 소량의 방사성 추적자를 정맥 주사로 환자에게 투여합니다. 추적자는 암세포를 포함하여 빠르게 분열하는 세포에 신속하게 흡수되어 영상 결과에서 강조 표시됩니다. 환자는 유방 조영술 기계와 유사한 특수 플랫폼에 유방을 올려놓습니다. 유방을 부드럽게 압박하여 특수 감마 카메라로 고품질 이미지를 촬영하지만, 이 가벼운 압박은 불편함을 유발하지 않습니다. 감마 카메라는 약 20분 동안 유방 조직의 활동을 기록합니다.
시장 동향: 성장 요인
유방암 검진을 위한 분자 유방 영상 기술의 도입 증가
유방암 검진을 위한 분자 유방 영상 기술의 도입이 증가함에 따라 예측 기간 동안 시장이 성장할 것으로 예상됩니다. 분자 유방 영상 기술은 특히 유방 조직이 치밀한 여성에서 유방암을 탐지하는 데 높은 민감도를 보이는 것으로 알려져 있습니다. 유방 촬영술만으로는 발견하지 못할 수 있는 종양을 식별하는 데 도움이 될 수 있습니다. 이러한 정확도 향상은 분자 유방 영상 기술 도입의 중요한 동인입니다.
또한 분자 유방 영상 기술은 유방 촬영술과 함께 보완적인 검진 도구로 자주 사용됩니다. 유방 촬영 결과가 불확실하거나 추가 정보가 필요한 경우, 이 영상 기술은 암 진단 누락 또는 지연 위험을 줄여 귀중한 정보를 제공할 수 있습니다.
이 영상 기술의 지속적인 발전으로 접근성이 향상되고 사용이 더욱 간편해졌습니다. 디지털 감마 카메라 개발 및 더욱 편리해진 영상 촬영 절차와 같은 기술적 발전으로 인해 더욱 매력적인 선택지가 되었습니다. 유방암 가족력이 있거나 BRCA1 및 BRCA2와 같은 유전적 변이가 있는 고위험 환자에게 자주 권장됩니다. 암을 조기에 발견하는 능력은 이러한 환자들의 생명을 구할 수 있습니다.
예를 들어, 2021년 2월 9일, 스마트브레스트(SmartBreast Corporation)는 폭스세미콘 인티그레이티드 테크놀로지스(FoxSemicon Integrated Technologies, Inc., FITI)와 분자 유방 영상(MBI) 시스템 제조를 위한 파트너십을 체결했다고 발표했습니다. FITI는 스마트브레스트에 상당한 투자를 했으며, 스마트브레스트가 최근 인수한 GE 헬스케어 디스커버리 NM 750b와 딜론 테크놀로지스 D6800 두 가지 MBI 시스템의 위탁 제조업체가 될 예정입니다. 스마트브레스트는 이 두 시스템을 각각 EVE CLEAR SCAN e750과 e680으로 브랜드명을 변경할 것입니다. SmartBreast와 FITI는 협력하여 혁신적이고 비용 효율적인 차세대 MBI 시스템을 공동 개발 및 제조함으로써 암을 조기에 발견하는 효율성을 높이고 보급률을 확대할 것입니다.
또한, 유방암 발병률 증가, 유방암 진단을 위한 새롭고 진보된 분자 영상 기술에 대한 FDA 승인 증가, 더욱 발전된 기기 개발을 위한 임상 시험 증가, 분자 유방 영상 기기에 대한 인식 제고 및 개발 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제한 요인
분자 유방 영상과 관련된 합병증, 높은 검사 비용, 모든 암을 진단할 수 없는 한계, 분자 유방 영상에 사용되는 추적자에 의한 알레르기 반응 발생 가능성 등은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
글로벌 분자 유방 영상 시장은 설계 유형, 모달리티, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.
감마 카메라 부문은 분자 유방 영상 시장 점유율의 약 45.3%를 차지했습니다.
감마 카메라 부문은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 분자 유방 영상에서 감마 카메라는 방사성 추적자를 주입한 후 유방 조직 이미지를 촬영하는 데 주로 사용됩니다. 이 카메라는 추적자에서 방출되는 감마선을 감지하는데, 이 감마선은 유방암 종양과 같이 대사 활동이 활발한 부위에 우선적으로 흡수됩니다.
또한, 감마 카메라의 높은 감도는 유방 내 작거나 활동성이 낮은 종양까지도 탐지하는 데 매우 중요합니다. 감마 카메라를 이용한 분자 유방 영상은 여성들이 유방 건강을 적극적으로 관리할 수 있는 또 다른 방법을 제공합니다. 최신 감마 카메라는 빠른 이미지 획득과 환자의 방사선 노출량 감소를 통해 효율성을 극대화하도록 설계되었습니다. 효율성은 환자의 편안함에 영향을 미치므로 매우 중요한 요소입니다.
더불어, 분자 유방 영상에 사용되는 감마 카메라는 종종 고급 이미지 처리 및 분석 소프트웨어를 탑재하고 있습니다. 이러한 도구는 방사선 전문의가 이미지를 해석하는 데 도움을 주어 진단 과정에서 필수적인 역할을 합니다. 감마 카메라의 디자인과 기능은 환자의 경험에 큰 영향을 미칠 수 있습니다. 편안하고 잘 설계된 카메라는 분자 유방 영상 검사 과정에서 환자의 불안감을 줄이고 전반적인 경험을 개선하는 데 도움이 됩니다.

지리적 분석
북미 지역은 시장 점유율의 약 40.3%를 차지했습니다.
북미 지역은 주요 업체들의 강력한 입지와 활발한 연구 활동으로 인해 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국은 진단 회사 및 의료 기기 회사와 같은 주요 업체들이 밀집해 있는 중심지입니다. 주요 업체들은 기술 발전을 통해 더욱 발전된 분자 유방 영상 기술 개발에 적극적으로 집중하여 더 나은 환자 치료 결과와 함께 활용도를 높이고 있습니다.
또한, 이 지역의 유방암 발병률이 매우 높은 것도 시장 성장을 견인하는 요인으로 작용합니다. 높은 유방암 발병률로 인해 유방암 진단 및 검진의 활용도가 높아지고 있습니다. 조기 발견 및 진단은 환자의 사망률을 낮추는 데 기여합니다.
예를 들어, 미국 국립보건원(NIH)의 2021년 자료에 따르면, 미국에서는 매년 25만 건 이상의 유방암 신규 환자가 발생하고 4만 6천 명 이상의 여성이 이 질병으로 사망합니다. 지난 20년간 유방암 사망률은 40% 이상 감소하는 괄목할 만한 성과를 거두었습니다. 이는 조기 발견 기술의 발전과 더욱 정교해진 표적 치료법 덕분입니다. 유방암을 조기에 발견할 경우, 여성의 95% 이상이 5년 이상 생존합니다.
경쟁 환경
분자 유방 영상 시장의 주요 글로벌 기업으로는 CMR Naviscan Corporation, SmartBreast Corporation, DIGIRAD HEALTH, INC. 등이 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 분자 유방 영상 시장에 상당한 영향을 미쳤습니다. 팬데믹 기간 동안, 팬데믹과 관련된 위험에 대한 관심이 집중되면서 분자 유방 영상 시술이 일시적으로 연기되거나 취소되었습니다. 사람들이 정기 검진을 미루면서 분자 유방 영상 환자 수가 감소했습니다. 팬데믹은 분자 유방 영상 시스템에 필요한 부품 및 재료의 공급망을 교란시켰습니다. 이러한 부품의 제조 및 유통 지연은 영상 장비의 공급에 영향을 미쳤습니다.

시장 세분화
설계 유형별
• 방사성 추적자
• 특수 카메라
모달리티별
• 단일 헤드 감마 카메라
• 이중 헤드 카메라
적용 분야별
• 유방 검진
• 유방 진단
최종 사용자별
• 병원
• 진단 센터
• 전문 클리닉
• 학술 및 연구 기관
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 설계 유형, 모달리티, 적용 분야, 최종 사용자 및 지역별 글로벌 분자 유방 영상 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악하기 위함입니다.

• 트렌드 분석 및 공동 개발을 통해 상업적 기회를 파악합니다.
• 모든 세그먼트를 포함한 분자 유방 영상 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료를 Excel 파일로 제공합니다.
글로벌 분자 유방 영상 시장 보고서는 약 48개의 표, 59개의 그림, 187페이지 분량입니다.
2023년 주요 고객
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global molecular breast imaging market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Molecular breast imaging also known as scintimammography, nuclear medicine breast imaging and breast-specific gamma imaging, is an advanced and FDA-approved imaging technology that is used to identify breast cancer in women with dense breast tissue. Molecular breast imaging uses a special camera and a small amount of radioactive tracer to spotlight differences in tissue activity and differentiate healthy, dense tissue from breast irregularities. It is a highly accurate imaging study with a low chance of missing cancerous cells.
Moreover, a small amount of radioactive tracer is administered to the patient through an intravenous line. The tracer is swiftly absorbed by rapidly dividing cells, including cancer cells, and appears highlighted on imaging results. The patient places her breast on a special platform which is similar to that of a mammogram machine. The breast is gently compressed to capture high-quality images with a special gamma camera, but this light compression should not cause discomfort. The gamma cameras record the breast’s tissue activity for about 20 minutes.
Market Dynamics: Drivers
Increasing adoption of molecular breast imaging for breast cancer screening
The increasing adoption of molecular breast imaging for breast cancer screening is expected to drive the market over the forecast period. Molecular breast imaging is known for its higher sensitivity in detecting breast cancer, particularly in women with dense breast tissue. It can help identify tumors that might be missed by mammography alone. This increased accuracy is a significant driver of its adoption.
Moreover, molecular breast imaging is often used as a complementary screening tool alongside mammography. Also, in cases where the mammograms yield inconclusive results or when additional information is needed, this imaging technique can provide valuable insights by reducing the risk of missed or delayed cancer diagnoses.
Ongoing advancements in this imaging technology have made it more accessible and easier to use. These technological improvements like the development of digital gamma cameras and more comfortable imaging procedures, make it a more attractive option. It is often recommended for high-risk patients such as those with a family history of breast cancer or known genetic mutations like BRCA1 and BRCA2. The ability to detect cancer at an earlier stage can be lifesaving for these individuals.
For instance, on February 9, 2021, SmartBreast Corporation released that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture Molecular Breast Imaging (MBI) systems. FITI has invested substantially in SmartBreast and will be the contract manufacturer for two MBI systems recently acquired by SmartBreast, the GE Healthcare Discovery NM 750b and the Dilon Technologies D6800. SmartBreast will rebrand the two systems as EVE CLEAR SCAN e750 and e680, respectively. Together, SmartBreast and FITI will co-develop and manufacture innovative, cost-effective, next-generation MBI systems to further increase the efficacy of detecting cancer in the earlier stage and to increase the adoption.
Further, the increasing prevalence of breast cancers, rising FDA approvals for novel and advanced molecular imaging techniques for breast, increasing clinical trials to develop more advanced devices, increasing awareness and advancements in the development of molecular breast imaging devices are the factors expected to drive the market over the forecast period.
Restraints
Factors such as complications associated with molecular breast imaging, the high cost of associated with this imaging technique, this test can't detect all cancers and the tracer in the molecular breast imaging can develop allergic reactions are expected to hamper the market.
Segment Analysis
The global molecular breast imaging market is segmented based on design type, modality, application, end-user and region.
The gamma camera segment accounted for approximately 45.3% of the molecular breast imaging market share
The gamma camera segment is expected to hold the largest market share over the forecast period. The gamma camera in molecular breast imaging is mainly responsible for capturing images of the breast tissue after the injection of a radioactive tracer. It detects gamma rays emitted from the tracer, which is preferentially taken up by areas with increased metabolic activity, such as breast cancerous tumors.
Furthermore, the sensitivity of the gamma camera is crucial in detecting even small or low-activity tumors in the breast. This molecular breast imaging which consists of the gamma camera offers another option for women to be proactive about their breast health. Modern gamma cameras are designed for efficiency by allowing for quicker image acquisition and reduced radiation exposure for patients. Efficiency is a vital consideration, as it impacts patient comfort.
Additionally, the gamma cameras of molecular breast imaging often come equipped with advanced image processing and analysis software. These tools aid radiologists in interpreting the images, making the camera an integral part of the diagnostic process. The design and functionality of the gamma camera can significantly influence the patient's experience. A comfortable and well-designed camera can help reduce anxiety and improve the overall patient experience during the molecular breast imaging procedure.
Geographical Analysis
North America accounted for approximately 40.3% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is a hub for its strong presence of major players such as diagnostic companies and medical device companies. The presence of major players actively focusing on the development of more advanced molecular breast imaging by the technological advancements for better adoption along with better patient outcomes.
Furthermore, the increasing prevalence of breast cancer in the region is very high, which is considered to drive the market in the region. Due to the high prevalence of breast cancer in the region, it is known for the increased adoption for the diagnosis and screening of breast cancer. Early detection reduces the death rate of the patients by early detection and diagnosis.
For instance, according to the National Institute of Health (NIH), 2021, in the United States, there are over 250,000 new cases of breast cancer annually with over 46,000 women dying of the disease. Over the past two decades, the death rate from breast cancer has decreased by over 40%, a monumental achievement, due to the combination of improved detection as well as improved, increasingly targeted therapies. When breast cancer is detected early, over 95% of women survive more than five years.
Competitive Landscape
The major global players in the molecular breast imaging market include CMR Naviscan Corporation, SmartBreast Corporation and DIGIRAD HEALTH, INC. among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global molecular breast imaging market. During the pandemic, molecular breast imaging procedures are postponed or canceled temporarily due to the redirected focus on the pandemic and its associated risks. Molecular breast imaging experienced a drop in patient volumes as people postponed routine visits. The pandemic disrupted supply chains for the components and materials needed for molecular breast imaging systems. Delays in the manufacturing and distribution of these components affected the availability of these imaging equipment.
Market Segmentation
By Design Type
• Radioactive Tracer
• Special Camera
By Modality
• Single Head Gamma Camera
• Dual Head Camera
By Application
• Breast Screening
• Breast Diagnosis
By End-User
• Hospitals
• Diagnostic Centers
• Specialty Clinics
• Academic and Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global molecular breast imaging market segmentation based on design type, modality, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of molecular breast imaging market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global molecular breast imaging market report would provide approximately 48 tables, 59 figures, and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Design Type
3.2. Snippet by Modality
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption for Breast Cancer Screening
4.1.2. Restraints
4.1.2.1. Complications Associated with Molecular Breast Imaging
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Design Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
7.1.2. Market Attractiveness Index, By Design Type
7.2. Radioactive Tracer*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gamma Camera
8. By Modality
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
8.1.2. Market Attractiveness Index, By Modality
8.2. Single Head Gamma Camera*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Dual Head Camera
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.1.2. Market Attractiveness Index, By Application
9.2. Breast Screening*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Breast Diagnosis
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic Centers
10.4. Specialty Clinics
10.5. Academic and Research Institutes
10.6. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.2.5. 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Design Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. CMR Naviscan Corporation*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. SmartBreast Corporation
13.3. DIGIRAD HEALTH, INC.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

CMR Naviscan Corporation, 4.	Key Developments, SmartBreast Corporation, DIGIRAD HEALTH, INC.

표 목록 (Tables)

List of Tables

Table 1 Global Molecular Breast Imaging Market Value, By Design Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Molecular Breast Imaging Market Value, By Modality, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Molecular Breast Imaging Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Molecular Breast Imaging Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Molecular Breast Imaging Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Molecular Breast Imaging Market Value, By Design Type, 2022, 2026 & 2030 (US$ Million)

Table 7 Global Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 8 Global Molecular Breast Imaging Market Value, By Modality, 2022, 2026 & 2030 (US$ Million)

Table 9 Global Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 10 Global Molecular Breast Imaging Market Value, By Application, 2022, 2026 & 2030 (US$ Million)

Table 11 Global Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 12 Global Molecular Breast Imaging Market Value, By End-User, 2022, 2026 & 2030 (US$ Million)

Table 13 Global Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 14 Global Molecular Breast Imaging Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 15 Global Molecular Breast Imaging Market Value, By Region, 2021-2030 (US$ Million)

Table 16 North America Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 17 North America Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 18 North America Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 19 North America Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 20 North America Molecular Breast Imaging Market Value, By Country, 2021-2030 (US$ Million)

Table 21 South America Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 22 South America Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 23 South America Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 24 South America Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 25 South America Molecular Breast Imaging Market Value, By Country, 2021-2030 (US$ Million)

Table 26 Europe Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 27 Europe Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 28 Europe Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 29 Europe Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 30 Europe Molecular Breast Imaging Market Value, By Country, 2021-2030 (US$ Million)

Table 31 Asia-Pacific Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 32 Asia-Pacific Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 33 Asia-Pacific Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 34 Asia-Pacific Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 35 Asia-Pacific Molecular Breast Imaging Market Value, By Country, 2021-2030 (US$ Million)

Table 36 Middle East & Africa Molecular Breast Imaging Market Value, By Design Type, 2021-2030 (US$ Million)

Table 37 Middle East & Africa Molecular Breast Imaging Market Value, By Modality, 2021-2030 (US$ Million)

Table 38 Middle East & Africa Molecular Breast Imaging Market Value, By Application, 2021-2030 (US$ Million)

Table 39 Middle East & Africa Molecular Breast Imaging Market Value, By End-User, 2021-2030 (US$ Million)

Table 40 CMR Naviscan Corporation: Overview

Table 41 CMR Naviscan Corporation: Product Portfolio

Table 42 CMR Naviscan Corporation: Key Developments

Table 43 SmartBreast Corporation: Overview

Table 44 SmartBreast Corporation: Product Portfolio

Table 45 SmartBreast Corporation: Key Developments

Table 46 DIGIRAD HEALTH, INC.: Overview

Table 47 DIGIRAD HEALTH, INC.: Product Portfolio

Table 48 DIGIRAD HEALTH, INC.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 2 Global Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 3 Global Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 4 Global Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 5 Global Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 6 Global Molecular Breast Imaging Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Molecular Breast Imaging Market Y-o-Y Growth, By Design Type, 2022-2030 (%)

Figure 8 Radioactive Tracer Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 9 Gamma Camera Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 10 Global Molecular Breast Imaging Market Y-o-Y Growth, By Modality, 2022-2030 (%)

Figure 11 Single Head Gamma Camera Modality in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 12 Dual Head Camera Modality in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 13 Global Molecular Breast Imaging Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 14 Breast Screening Application in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 15 Breast Diagnosis Application in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 16 Global Molecular Breast Imaging Market Y-o-Y Growth, By End-User, 2022-2030 (%)

Figure 17 Hospitals End-User in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 18 Diagnostic Centers End-User in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 19 Specialty Clinics End-User in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 20 Academic and Research Institutes End-User in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 21 Others End-User in Global Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 22 Global Molecular Breast Imaging Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 24 Asia-Pacific Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 25 Europe Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 26 South America Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 27 Middle East and Africa Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 28 North America Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 29 North America Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 30 North America Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 31 North America Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 32 North America Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 33 North America Molecular Breast Imaging Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 35 South America Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 36 South America Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 37 South America Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 38 South America Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 39 South America Molecular Breast Imaging Market Share, By Country, 2022 & 2030 (%)

Figure 40 Europe Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 41 Europe Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 42 Europe Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 43 Europe Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 44 Europe Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 45 Europe Molecular Breast Imaging Market Share, By Country, 2022 & 2030 (%)

Figure 46 Asia-Pacific Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 47 Asia-Pacific Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 49 Asia-Pacific Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 50 Asia-Pacific Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 51 Asia-Pacific Molecular Breast Imaging Market Share, By Country, 2022 & 2030 (%)

Figure 52 Middle East & Africa Molecular Breast Imaging Market Value, 2021-2030 (US$ Million)

Figure 53 Middle East & Africa Molecular Breast Imaging Market Share, By Design Type, 2022 & 2030 (%)

Figure 54 Middle East & Africa Molecular Breast Imaging Market Share, By Modality, 2022 & 2030 (%)

Figure 55 Middle East & Africa Molecular Breast Imaging Market Share, By Application, 2022 & 2030 (%)

Figure 56 Middle East & Africa Molecular Breast Imaging Market Share, By End-User, 2022 & 2030 (%)

Figure 57 CMR Naviscan Corporation: Financials

Figure 58 SmartBreast Corporation: Financials

Figure 59 DIGIRAD HEALTH, INC.: Financials

글로벌 분자 유방 영상 시장 – 2023-2030

Global Molecular Breast Imaging Market - 2023-2030